Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective

Chronic inflammatory diseases like psoriasis, Crohn’s disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized as disease entities, where dysregulated cytokines contribute substantially to tissue-specific inflammation. A dysregulation in the IL-23/IL-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwicky, Pascale, Unger, Susanne, Becher, Burkhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037236/
https://www.ncbi.nlm.nih.gov/pubmed/31727781
http://dx.doi.org/10.1084/jem.20191123
_version_ 1783500379885928448
author Zwicky, Pascale
Unger, Susanne
Becher, Burkhard
author_facet Zwicky, Pascale
Unger, Susanne
Becher, Burkhard
author_sort Zwicky, Pascale
collection PubMed
description Chronic inflammatory diseases like psoriasis, Crohn’s disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized as disease entities, where dysregulated cytokines contribute substantially to tissue-specific inflammation. A dysregulation in the IL-23/IL-17 axis can lead to inflammation of barrier tissues, whereas its role in internal organ inflammation remains less clear. Here we discuss the most recent developments in targeting IL-17 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chronic inflammatory diseases.
format Online
Article
Text
id pubmed-7037236
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-70372362020-07-06 Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective Zwicky, Pascale Unger, Susanne Becher, Burkhard J Exp Med Reviews Chronic inflammatory diseases like psoriasis, Crohn’s disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), and others are increasingly recognized as disease entities, where dysregulated cytokines contribute substantially to tissue-specific inflammation. A dysregulation in the IL-23/IL-17 axis can lead to inflammation of barrier tissues, whereas its role in internal organ inflammation remains less clear. Here we discuss the most recent developments in targeting IL-17 for the treatment of chronic inflammation in preclinical models and in patients afflicted with chronic inflammatory diseases. Rockefeller University Press 2019-11-14 /pmc/articles/PMC7037236/ /pubmed/31727781 http://dx.doi.org/10.1084/jem.20191123 Text en © 2019 Zwicky et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Reviews
Zwicky, Pascale
Unger, Susanne
Becher, Burkhard
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title_full Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title_fullStr Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title_full_unstemmed Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title_short Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
title_sort targeting interleukin-17 in chronic inflammatory disease: a clinical perspective
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037236/
https://www.ncbi.nlm.nih.gov/pubmed/31727781
http://dx.doi.org/10.1084/jem.20191123
work_keys_str_mv AT zwickypascale targetinginterleukin17inchronicinflammatorydiseaseaclinicalperspective
AT ungersusanne targetinginterleukin17inchronicinflammatorydiseaseaclinicalperspective
AT becherburkhard targetinginterleukin17inchronicinflammatorydiseaseaclinicalperspective

Ejemplares similares